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ABSTRACT
Objective: This study aimed to determine clopidogrel in plasma to obtain its pharmacokinetic profile using ultra-high-performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS).
Methods: Clopidogrel analysis was performed in vivo by UPLC-MS/MS using validated methods. Subjects received 75 mg clopidogrel, and plasma 
samples were collected at 14 time points after 0 baseline (pre-dose): 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 8, 12, 18, and 24 h.
Results: A linear calibration curve was produced in the range of 20–5.000 pg/mL. This method fulfills the criteria for validation according to the 
European Medicines Agency guidelines. The obtained pharmacokinetic profile of clopidogrel was as follows: Maximum concentration=1.146 ng/mL, 
time at maximum concentration (tmax)=1 h, half-life (t½)=7.01 h, area under curve (AUC)0−t=7.420 ng h/mL, and AUC0−t=8.111 ng h/mL.
Conclusion: Clopidogrel analysis using a UPLC/MS-MS system with liquid-liquid extraction method was successfully conducted using plasma samples 
from three healthy subjects who administered 75 mg of clopidogrel tablet.
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INTRODUCTION
Clopidogrel is a cardiovascular drug that functions as a platelet 
aggregation inhibitor. It prevents the formation of blood clots through 
adenosine diphosphate blockage by binding with P2Y12 receptors on the 
surface, causing GPIIb/IIIa glycoprotein complex inactivation such that 
platelets do not clot. Clopidogrel belongs to the thienopyridine group of 
chemicals and is metabolized by the CYP450 enzyme in the liver, which 
produces active and inactive metabolites. The active metabolites bind 
with platelet receptors in a fast and irreversible way [1].
As a cardiovascular drug indicated for serious conditions, clopidogrel 
requires a bioequivalence test [2]. Clopidogrel metabolites can convert 
back into clopidogrel. The responsible clopidogrel form that causes 
reconversion is clopidogrel acyl glucuronide, which is altered from 
carboxylic clopidogrel by the UDP-glucuronyltransferase enzyme. The 
level of clopidogrel acyl glucuronide in the blood can reach 500 times 
higher than the level of clopidogrel; thus, clopidogrel levels measured 
in plasma often do not reflect actual levels [3-6].
Drug bioequivalence testing should use a validated bioanalysis method. 
A selective and sensitive measurement technique is required to measure 
the smallest level of drug still present in the blood [7]. The maximum 
concentrations (Cmax) of clopidogrel reported in previous research were 
2.10 ng/mL, 1.70 ng/mL, and 1.86 ng/mL [5-7]. Based on previous 
research, the LLOQ value should be obtained at 85 pg/mL, that is, 5% of 
clopidogrel Cmax. In this research, the analytical method was developed 
for determining clopidogrel in plasma to obtain its pharmacokinetic 
profile using LC-tandem mass spectrometry (MS)/MS.
MATERIALS AND METHODS
Study design
As a pilot study, three healthy subjects were given one clopidogrel 
tablet at a dose of 75 mg after fasting. The subjects met the exclusion 
and inclusion criteria. According to the Food and Drug Administration, 
pilot studies can be done with a small number of subjects before full 
bioequivalence studies [8,9]. Blood samples were collected at 14 time 
points, namely 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 8, 12, 18, 
and 24 h, and then analyzed using validated bioanalytical methods. The 
sampling time should be 3 or more times the half-life. The half-life of 
clopidogrel was reported as 6.9 h in a previous study [10].
Before blood samples were taken, each subject was given an explanation 
of the research and provided informed consent. This study was 
approved by the Medical Research Ethics Committee of Medical Faculty, 
Universitas Indonesia (No.306/UN2.F1/ETIK/III/2017).
Tools
This study used a set of ultra-high-performance liquid chromatography 
(UPLC)-MS/MS (Waters Xevo TQD Triple Quadrupole) including a 
Quaternary Solvent Manager (Acquity UPLC H-Class), Sample Manager 
(Acquity UPLC), nitrogen generator compressor (PEAK Scientific), BEH C18 
Column (Waters Acquity™ UPLC 1.7 µm, 2.1 mm×100 mm), mass analyzer 
of triple quadrupole (Xevo TQD) with an ionization source (Zspray™), 
Data Processing Software (MassLynx Software), a computer (Lenovo), 
microcentrifuge tubes, autosampler vials, 0.2 µm Millipore membrane, 
analytical balance, ultrasonic stirrer (Elmasonic), refrigerator, freezer, gas 
remover (Elmasonic S40H), vortex (Maxi Mix II), and glassware.
Materials
The blank plasma from Indonesian Red Cross and plasma samples 
isolated from the blood of three healthy subjects given a 75 mg 
clopidogrel tablet (single dose). Additional materials included standard 
clopidogrel (MSN Laboratories), irbesartan as an internal standard 
(Zhejiang Huahai Pharmaceutical), HPLC grade aquabidest (Merck), 
HPLC grade acetonitrile (Merck), formic acid (Merck), diethyl ether 
(Merck), ammonium acetate (Merck), and Plavix tablet containing 
75 mg clopidogrel.
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Stock solution
Clopidogrel and irbesartan (internal standard) were weighed to 
10.0 mg and dissolved in acetonitrile to a concentration of 0.1 mg/mL. 
Dilution was performed to achieve certain concentrations.
System suitability test
As much as 5 l of the mixture of clopidogrel and irbesartan solution at a 
concentration of 100 ng/mL was injected into the UPLC-MS/MS system, 
and evaluate the CV of retention times and area of analytes and internal 
standards.. The repeated value coefficient of variation percentage (% 
CV) results from five injections were recorded and calculated as the 
ratio of area and retention time of the analyte and internal standard.
Sample preparation
A volume of 250 µL plasma containing the analyte was mixed with as 
much as 20 µL of irbesartan solution at a concentration of 100 ng/mL. 
The sample was mixed by vortex for 30 s. Extraction was done by 
the liquid-liquid extraction. The sample was mixed with as much as 
250 µL of 50 mM ammonium acetate (pH 6.8) and vortexed for 10 s. 
Next, 1 mL of diethyl ether was added and vortexed for 2 min followed 
by centrifugation at 3000 rpm for 10 min. After the supernatant was 
separated, 800 µL of the organic phase was transferred to another 
microtube for evaporation at 10 min at 60°C. The residue was then 
reconstituted in 150 µL acetonitrile and vortexed for 10 s. Finally, 5 μL 
of the aliquot was injected to UPLC-MS/MS.
Validation of bioanalysis methods [11].
Calibration curves
A total of 8 plasma samples with clopidogrel concentrations of 20, 100, 
200, 1000, 2500, 4000, and 5000 pg/mL, 20 µL of the internal standard 
100 ng/mL, blank samples (plasma without internal standard), and 
zero samples (plasma with internal standard) were prepared. A total of 
10 µL of the final solution for each concentration was injected into the 
UPLC-MS/MS system. The peak area obtained was recorded, and then 
the calibration curve was made. Linearity was determined by the linear 
regression equation and calculation of the correlation coefficient (r). The 
calculation of percentage difference with the limit values of percentage 
difference was <±15% for all concentrations, except LLOQ not >20%.
Within-run accuracy and precision
Aliquots from a plasma blank were prepared and mixed with QC 
solutions at low (QCL), medium (QCM), and high (QCH) concentrations 
with the addition of 20 µl of the 100 ng/mL internal standard. Samples 
were prepared, and 10 µL of the final solution was injected into the 
UPLC-MS/MS system. The test was performed with five replicas. The 
percentage difference and percentage CV values were calculated 
to determine accuracy and precision, respectively. The percentage 
difference and percentage CV values did not exceed 15±% for all 
concentrations except LLOQ, which did not exceed ±20%.
Preparation and collection of healthy subject blood samples
Blood samples were collected before and after healthy subjects 
administered 75 mg clopidogrel tablet. Post-dose samples were 
collected at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 8, 12, 18, and 24 h. Samples 
were taken by a phlebotomist using the venipuncture technique and a 
syringe. Samples were collected in 9 mL in vacuum tubes containing 
heparin anticoagulant. Plasma was isolated from the blood and then 
prepared and analyzed using UPLC-MS/MS.
Pharmacokinetics calculations
The obtained data were used to calculate clopidogrel levels. The 
pharmacokinetics calculations were performed using the following 
parameters: Cmax, time at maximum concentration (tmax), t½ (half-life), 
area under curve (AUC)0−t, and AUC0−∞.
RESULTS AND DISCUSSION
System suitability test
After the optimum conditions were confirmed, a system suitability test 
was performed to ensure that the analysis provided good and consistent 
results. The system suitability test was performed on a mixture of 
100 ng/mL clopidogrel and 100 ng/mL irbesartan. The mixed solution 
was injected 5 times in 5 µl injection volumes, and then the percentage 
CV from the retention time and the peak area of analyte and internal 
standard were obtained. For clopidogrel, the CV was equal to 0.247% 
for area and 0.202% for retention time. For irbesartan, the CV was equal 
to 0.784% for area and 0.462% for retention time. The results of the 
system suitability test fulfilled the requirement of ≤2% of percentage 
CV for area and retention time.
Validation of bioanalysis methods
Calibration curves
The range of the calibration curve for clopidogrel was 
20–5000 pg/mL based on the seven concentrations, namely 20, 100, 
200, 1000, 2500, 4000, and 5000 pg/mL plus the blank and zero 
samples. The correlation coefficient was 0.9987 with a linear regression 
equation y=0.1585+0.0009x. These data show that the obtained 
calibration curve was linear. The percentage difference value for the 
clopidogrel calibration curve fulfilled the requirements of 11.86% at 
LLOQ concentrations and −8.57% to 14.16% at other concentrations. 
The LLOQ value of clopidogrel was good because it could measure 
concentrations up to 20 pg/mL. However, the obtained LLOQ was still 
higher than that reported by Robinson et al. of 10 pg/mL [12]. The 
clopidogrel analysis method used in this study can be applied in in vivo 
with a LLOQ value of 20 pg/mL because the LLOQ value requirement is 
at least 5% Cmax clopidogrel.
Within-run accuracy and precision
The within-run accuracy and precision were performed to determine 
the proximity between the measured concentrations and actual 
concentrations, as well as the proximity of repeatable analytical 
measurements, by determining the percentage difference values 
for accuracy and percentage CV values for precision. The accuracy 
and precision requirements are ≤±20% at LLOQ concentrations and 
≤±15% at other concentrations. The results of the within-run accuracy 
for clopidogrel fulfilled the requirements with percentage difference 
values of −1.06–13.80% at LLOQ concentration and −4.17–14.86% at 
other concentrations. The within-run precision for clopidogrel also met 
the requirements with percentage CV values of 6.60% at LLOQ, 6.18% 
on QCL, 5.01% on QCM, and 4.65% on QCH. Although the percentage 
difference and percentage CV values obtained were different from 
previous studies, the accuracy and precision results still met the 
requirements and showed that the analytical methods used here were 
accurate and precise.
Sample analysis
The sample analysis, calibration curve, and QC sample results for 
each subject are presented in Table 1. The measured clopidogrel 
concentrations in plasma are plotted as plasma concentration versus 
time curves in Figs. 1-3. The Cmax values from subjects 1, 2, and 3 were 
1.07, 1.11, and 1.25 ng/mL, respectively, with an average of 1.15 ng/
mL. The tmax value for subjects 1 and 3 was 1 h, whereas the tmax value 
for 2 was 1.25 h. The Cmax and tmax values indicated the absorption 
rate of a drug in the body. The Cmax value shows the maximum drug 
concentration in plasma after drug administration. The tmax value is 
the time when the drug concentration in plasma reaches its peak, and 
the absorption of the drug is greatest, and when the drug absorption 
rate is equal to the drug elimination rate. The low tmax value indicates 
that the drug absorption rate is rapid. The average Cmax value of 5% in 
this study was about 57.5 pg/mL; this value is greater than the LLOQ 
value obtained using this method, namely 20 pg/mL. This value meets 
the EMA requirement that LLOQ should not be >5% of the Cmax of the 
analyte in the body (Cmax). These results suggest that the validated 
analytical methods were successfully applied in vivo.
AUC0−t, AUC0−∞, and t½ (half-life) were measured by plotting the data of 
plasma drug concentration versus time. The AUC0−t values for subjects 
1, 2, and 3 were 7.87, 6.69, and 7.69 ng h/mL, respectively, with an 
average of 7.420 ng h/mL. The AUC0−∞ values for subjects 1, 2, and 3 
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were 8.84, 7.36, and 8.58 ng h/mL, respectively, with an average of 
8.111 ng h/mL. The t½ values for subjects 1, 2, and 3 were 5.49, 7.63, 
and 7.92 h, respectively, with an average of 7.01 h.
The tmax obtained in this study did not differ greatly from that reported 
in previous work, which was about 1 h. However, the Cmax value obtained 
was substantially lower - almost half - of that reported by Karaźniewicz-
Łada et al. [8].
The AUC0−t and AUC0−∞ values were larger than those reported in 
the previous three studies, and the difference is considerable when 
compared with findings from Reddy et al. The AUC value is useful as a 
measurement of the total number of active drugs that reach the systemic 
circulation. The AUC0−t value was obtained from the AUC value at a zero-
time concentration to the AUC value at the last measured concentration 
or 24 h, whereas the AUC0−∞ value is the value of AUC obtained at the 
concentration of time 0 to infinite time. According to the bioequivalence 
test manual of Brachial Plexus Outcome Measure, the AUC0−t value 
obtained should be >80% of the AUC0−∞. The average AUC0−t value in 
this study met the criteria of 7.420 ng h/mL since it was >80% of the 
average AUC0−∞, that is, 8.110 ng h/mL, indicating that determination 
of the sampling time was optimal. In pharmacokinetics studies, AUC is 
the most relevant parameter for bioavailability assessment because it 
describes the total amount of drug absorbed and present in systemic 
circulation.
The t½ value, which is the time taken for half the concentration of 
drug to be eliminated, obtained in this study was also greater than that 
reported in previous studies of 7.013 h but not much different than that 
reported by Zou et al. of 6.9 h. The half-life can be affected by metabolic 
processes and excretion [10].
Differences in these values compared with previous studies may be 
due to differences in tablet formulation. Differences in outcomes may 
also be due to subject differences, such as differences in metabolic 
rates and excretions between racial groups. In this study, different 
pharmacokinetics profiles were obtained between subjects, although 
the differences were not statistically significant, suggesting differences 
in the activities carried out by the subject during the sampling process.
CONCLUSION
Clopidogrel analysis using a UPLC-MS/MS with liquid-liquid extraction 
method was carried out using plasma samples from three healthy 
subjects who administered 75 mg of clopidogrel tablet. The linear 
calibration curve obtained was in the range of 20–5000 pg/mL. The 
obtained pharmacokinetics profile had average values as follows: 
Cmax=1.146 ng/mL, tmax=1 h, t½=7.01 h, AUC0−t = 7.420 ng h/mL, and 
AUC0−∞ = 8.111 ng h/mL.
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